AngioDynamics Acquires RadiaDyne for an Undisclosed Sum

It continues to be a busy week for M&A in the medtech industry. This time around AngioDynamics is making a play to acquire RadiaDyne, the developer of a radiation dose monitoring platform, for an undisclosed sum. The deal is set to close at the end of September. This transaction expands Latham, NY-based AngioDynamics’ growing Oncology business by adding RadiaDyne’s early-stage, OARtrac real-time radiation dose monitoring platform and other market-leading oncology solutions, including the IsoLoc/ImmobiLoc and Alatus balloon stabilizing technologies. The acquisition follows AngioDynamics’ acquisition of the BioSentry Tract Sealant System from Surgical Specialties for an undisclosed amount in August. “The acquisition of RadiaDyne, combined with our recent BioSentry asset purchase, delivers on our commitment to build a world-class oncology portfolio,” Jim Clemmer, president and CEO of AngioDynamics said in a release. “We believe that together, these disruptive, patient-focused technologies will deliver safer, clinically-relevant, economically-favorable solutions for patients. This combination will significantly expand our value proposition and meaningfully change how care is delivered.” During a July earnings call, AngioDynamics CEO Jim Clemmer assured investors the company was able to execute M&A opportunities either in terms of acquisitions or di...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news